Amgen (AMGN)
(Real Time Quote from BATS)
$331.06 USD
-4.47 (-1.33%)
Updated Aug 2, 2024 02:56 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Amgen Inc. [AMGN]
Reports for Purchase
Showing records 421 - 434 ( 434 total )
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Modest topline growth & high single digit EPS growth expected over next five years, driven by approval of Prolia (denosumab) in cancer & Part D reimbursement coming online in early CY11....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Likely approval of Prolia (denosumab) in cancer to ensure modest topline growth & mid-to-high single digit EPS growth over next five years....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Events for the Week of October 24
Provider: WEDBUSH SECURITIES INC.
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Management?s revenue guidance for CY10 appears strong inlight of increasing competitive pressure faced by key products...
Provider: FIRST GLOBAL
Analyst: THOMAS K